Cargando…
Five-year results of a treatment program for chronic hepatitis B in Ethiopia
BACKGROUND: In sub-Saharan Africa, less than 1% of treatment-eligible chronic hepatitis B (CHB) patients receive antiviral therapy. Experiences from local CHB programs are needed to inform treatment guidelines and policies on the continent. Here, we present 5-year results from one of the first large...
Autores principales: | Desalegn, Hailemichael, Orlien, Stian Magnus Staurung, Aberra, Hanna, Mamo, Eyerusalem, Grude, Sine, Hommersand, Kristina, Berhe, Nega, Gundersen, Svein Gunnar, Johannessen, Asgeir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543851/ https://www.ncbi.nlm.nih.gov/pubmed/37775742 http://dx.doi.org/10.1186/s12916-023-03082-4 |
Ejemplares similares
-
High Seroprevalence of Autoantibodies Typical of Autoimmune Liver Disease in Eastern Ethiopia: Is Chewing of Khat (Catha edulis) a Triggering Factor?
por: Orlien, Stian Magnus Staurung, et al.
Publicado: (2018) -
Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study
por: Desalegn, Hailemichael, et al.
Publicado: (2019) -
Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa?
por: Desalegn, Hailemichael, et al.
Publicado: (2017) -
Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa
por: Aberra, Hanna, et al.
Publicado: (2017) -
Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia
por: Desalegn, Hailemichael, et al.
Publicado: (2018)